Igarashi Sae, Ishida Yusuke, Sekiguchi Shunya, Fujita Yosuke, Kawachi Aya, Tomino Mikiko
Department of Anesthesiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
JA Clin Rep. 2023 Jun 12;9(1):34. doi: 10.1186/s40981-023-00626-8.
Pulmonary endarterectomy (PEA) is a treatment modality for chronic thromboembolic pulmonary hypertension (CTEPH). PEA requires anesthesia management to prevent an increase in pulmonary vascular resistance (PVR) and circulatory failure. Therefore, it is necessary to select an anesthetic agent that can achieve these goals as much as possible. On the other hand, remimazolam, a short-acting sedative, was launched in Japan in 2020, and its use in various cases has been increasingly reported. This report demonstrates that remimazolam can be used safely in the anesthetic management of PEA.
A 57-year-old man was scheduled to undergo PEA for CTEPH. Remimazolam was used for sedation from induction of anesthesia. Hemodynamics were stable during surgery without circulatory failure. Anesthesia was managed intraoperatively without any particular increase in PVR.
Anesthesia was successfully managed without any complications. This case suggests that remimazolam is one of the options for anesthetic management in PEA.
肺动脉内膜剥脱术(PEA)是治疗慢性血栓栓塞性肺动脉高压(CTEPH)的一种治疗方式。PEA需要麻醉管理以防止肺血管阻力(PVR)增加和循环衰竭。因此,有必要选择一种能尽可能实现这些目标的麻醉剂。另一方面,短效镇静剂瑞马唑仑于2020年在日本上市,其在各种病例中的应用报道越来越多。本报告表明瑞马唑仑可安全用于PEA的麻醉管理。
一名57岁男性计划接受PEA治疗CTEPH。从麻醉诱导开始使用瑞马唑仑进行镇静。手术期间血流动力学稳定,无循环衰竭。术中麻醉管理未出现PVR特别增加的情况。
麻醉管理成功,无任何并发症。该病例表明瑞马唑仑是PEA麻醉管理的选择之一。